Isoprene Pharmaceuticals

Overview

Isoprene Pharmaceuticals, Inc. is a small molecular degrader company that spun out of the University of Maryland, Baltimore. The lead development candidate is a FIC MNK1/2 degrader that regulates oncogenic protein translation and is expected to be a monotherapy and used in combination to overcome cancer intrinsic and extrinsic resistance.